Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500762 | 0.89 | CA1 (0.32) | NR3C1PGRNR3C2AR | |
| SCHEMBL10213873 | 0.84 | CA1 (0.31) | — | |
| SCHEMBL10213876 | 0.84 | CA1 (0.31) | — | |
| SCHEMBL599785 | 0.80 | CA12 (0.30) | — | |
| SCHEMBL10213875 | 0.77 | NR3C1 (0.32) | NR3C1PGRNR3C2AR | |
| SCHEMBL14470727 | 0.72 | — | — | |
| SCHEMBL10213857 | 0.71 | CXCR2 (0.41) | NR3C1PGRNR3C2AR | |
| SCHEMBL500057 | 0.71 | IDO1 (0.37) | IDO1AGXT | |
| SCHEMBL14470726 | 0.69 | NR3C1 (0.32) | NR3C1PGRNR3C2AR | |
| SCHEMBL500146 | 0.68 | NR3C1 (0.34) | IDO1AGXTNR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968752-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20090239824-A1 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239824-A1 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | BTD, GAA, GBA3 | IDO1 2697/4885AGXT 317/4885NR3C1 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.